SAN DIEGO--(BUSINESS WIRE)--Inocras Inc., a U.S.-based precision medicine company, today announced a strategic partnership with AimedBio, a South Korean biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer. As part of the agreement, AimedBio has made a strategic equity investment in Inocras, and the two companies have signed a joint research agreement to integrate Inocras's whole genome sequencing (WGS) capabilities into AimedBio's clinical programs.Under the agreement